Nuo Therapeutics, Inc.
AURX · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $1,032 | $700 | $484 | $395 |
| % Growth | 47.4% | 44.6% | 22.7% | – |
| Cost of Goods Sold | $407 | $159 | $121 | $86 |
| Gross Profit | $625 | $541 | $363 | $308 |
| % Margin | 60.6% | 77.2% | 75% | 78.1% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,166 | $1,193 | $1,109 | $938 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,166 | $1,193 | $1,109 | $938 |
| Operating Income | -$540 | -$652 | -$745 | -$629 |
| % Margin | -52.3% | -93.1% | -153.8% | -159.4% |
| Other Income/Exp. Net | $2 | $2 | -$1 | $133 |
| Pre-Tax Income | -$538 | -$650 | -$746 | -$497 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$538 | -$650 | -$746 | -$497 |
| % Margin | -52.1% | -92.8% | -154% | -125.8% |
| EPS | -0.01 | -0.014 | -0.016 | -0.011 |
| % Growth | 28.1% | 12.6% | -50% | – |
| EPS Diluted | -0.01 | -0.014 | -0.016 | -0.011 |
| Weighted Avg Shares Out | 47,539 | 46,823 | 46,816 | 46,816 |
| Weighted Avg Shares Out Dil | 47,539 | 46,823 | 46,816 | 46,816 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $2 | $0 |
| Depreciation & Amortization | $41 | $41 | $3 | $28 |
| EBITDA | -$496 | -$611 | -$745 | -$601 |
| % Margin | -48.1% | -87.3% | -153.8% | -152.2% |